Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04613492 · ClinicalTrials.gov registry record · Phase 1
A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors
A Phase 1 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT04613492 is a Phase 1 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 40 participants.
The verdict
NCT04613492, a Phase 1 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
Study D7880C00001 is a first-in-human (FIH), Phase 1, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of MEDI9253 in combination with durvalumab in adult participants with select advanced/metastatic solid tumors.
Interventions
- BIOLOGICAL Durvalumab
- BIOLOGICAL MEDI9253
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2020-12-02 |
| Est. Completion | 2024-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04613492
The ClinicalTrials.gov registry entry for NCT04613492 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Durvalumab is the first listed.
NCT04613492 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04613492 about?
NCT04613492 is a clinical study titled "A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors". Study D7880C00001 is a first-in-human (FIH), Phase 1, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of MEDI9253 in combination with durvalumab in adult participants with select advanced/metastati...
What is the current status of trial NCT04613492?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2020-12-02. Estimated completion is 2024-05-31.
What interventions are being tested in trial NCT04613492?
The interventions under investigation include: Durvalumab (BIOLOGICAL), MEDI9253 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04613492?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.